Small Molecule Immunopotentiators as Vaccine Adjuvants

Vaccine Adjuvants and Delivery Systems

Volumn , Issue , 2006, Pages 175-189

  Xu, Fengfeng ^a   Valiante, Nicholas M ^a   Ulmer, Jeffrey B ^a  

^a MS X 600A   (United States)

Author keywords

Innate and adaptive immunity control by TLR signaling; Small molecule immunopotentiators (SMIPs) vaccine adjuvants; Toll like receptors (TLRs) and leucine rich repeat (LRR)

Indexed keywords

EID: 84889367411     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470134931.ch8     Document Type: Chapter

References (100)

1. Takea, K. & Akira, S. Toll-like receptors in innate immunity. Int Immunol 2005 Jan, 17(1), 1-14.
2. Janssens, S. & Beyaert, R. Role of Toll-like receptors in pathogen recognition. Clin Microbiol Rev 2003 Oct, 16(4), 637-646.
3. Murray, P.J. NOD proteins: An intracellular pathogen-recognition system or signal transduction modifiers? Curr Opin Immunol 2005 Aug, 17(4), 352-358.
4. Inohara, N., Chamaillard, M., McDonald, C. & Nunez, G. NOD-LRR proteins: role in host-microbial interactions and inflammatory disease. Annu Rev Biochem 2005, 74, 355-383.
5. Yoneyama, M., Kikuchi, M., Matsumoto, K., Imaizumi, T., Miyagishi, M., Taira, K. et al. Shared and unique functions of the DExD/H-box helicases RIG-I, MDA5, and LGP2 in antiviral innate immunity. J Immunol 2005 Sep 1, 175(5), 2851-2858.
6. Kato, H., Sato, S., Yoneyama, M., Yamamoto, M., Uematsu, S., Matsui, K. et al. Cell type-specific involvement of RIG-I in antiviral response. Immunity 2005 Jul, 23(1), 19-28.
7. Kato, H., Takeuchi, O., Sato, S., Yoneyama, M., Yamamoto, M., Matsui, K. et al. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 2006 May 4, 441(7089), 101-105.
8. Pasare, C. & Medzhitov, R. Control of B-cell responses by Toll-like receptors. Nature 2005 Nov 17, 438(7066), 364-368.
9. Hemmi, H. & Akira, S. TLR signalling and the function of dendritic cells. Chem Immunol Allergy 2005, 86, 120-135.
10. Baetz, A., Frey, M., Heeg, K. & Dalpke, A.H. Suppressor of cytokine signaling (SOCS) proteins indirectly regulate Toll-like receptor signaling in innate immune cells. J Biol Chem 2004 Dec 24, 279(52), 54708-54715.
11. Wald, D., Qin, J., Zhao, Z., Qian, Y., Naramura, M., Tian, L. et al. SIGIRR, a negative regulator of Toll-like receptor-interleukin 1 receptor signaling. Nat Immunol 2003 Sep, 4(9), 920-927.
12. Fukao, T. & Koyasu, S. PI3K and negative regulation of TLR signaling. Trends Immunol 2003 Jul, 24(7), 358-363.
13. Yoshida, H., Jono, H., Kai, H. & Li, J.D. The tumor suppressor cylindromatosis (CYLD) acts as a negative regulator for Toll-like receptor 2 signaling via negative cross-talk with TRAF6 AND TRAF7. J Biol Chem 2005 Dec 9, 280(49), 41111-41121.
14. Wang, Y., Tang, Y., Teng, L., Wu, Y., Zhao, X. & Pei, G. Association of beta-arrestin and TRAF6 negatively regulates Toll-like receptor-interleukin 1 receptor signaling. Nat Immunol 2006 Feb, 7(2), 139-147.
15. Boone, D.L., Turer, E.E., Lee, E.G., Ahmad, R.C., Wheeler, M.T., Tsui, C. et al. The ubiquitin-modifying enzyme A20 is required for termination of Toll-like receptor responses. Nat Immunol 2004 Oct, 5(10), 1052-1060.
16. Han, J. & Ulevitch, R.J. Limiting inflammatory responses during activation of innate immunity. Nat Immunol 2005 Dec, 6(12), 1198-1205.
17. Rehli, M. Of mice and men: species variations of Toll-like receptor expression. Trends Immunol 2002 Aug, 23(8), 375-378.
18. Nagai, Y., Garrett, K.P., Ohta, S., Bahrun, U., Kouro, T., Akira, S. et al. Toll-like receptors on hematopoietic progenitor cells stimulate innate immune system replenishment. Immunity 2006 Jun, 24(6), 801-812.
19. Re, F. & Strominger, J.L. Heterogeneity of TLR-induced responses in dendritic cells: from innate to adaptive immunity. Immunobiology 2004, 209(1-2), 191-198.
20. Pasare, C. & Medzhitov, R. Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science 2003 Feb 14, 299(5609), 1033-1036.
21. Ruprecht, C.R. & Lanzavecchia, A. Toll-like receptor stimulation as a third signal required for activation of human naive B cells. Eur J Immunol 2006 Apr, 36(4), 810-816.
22. Janssen, E., Tabeta, K., Barnes, M.J., Rutschmann, S., McBride, S., Bahjat, K.S. et al. Efficient T cell activation via a Toll-interleukin 1 receptor-independent pathway. Immunity 2006 Jun, 24(6), 787-799.
23. Nemazee, D., Gavin, A., Hoebe, K. & Beutler, B. Immunology: Toll-like receptors and antibody responses. Nature 2006 May 18, 441(7091), E4, discussion, E.
24. Pasare, C. & Medzhitov, R. Pasare and Medzhitov reply. Nature 2006 18 May, 441, E4.
25. Isaacs, A. & Lindenmann, J. Virus interference: I. The interferon. Proc R Soc Lond B Biol Sci 1957 Sep 12, 147(927), 258-267.
26. Krueger, R.E. & Mayer, G.D. Tilorone hydrochloride: an orally active antiviral agent. Science 1970 Sep 18, 169(951), 1213-1214.
27. Siminoff, P., Bernard, A.M., Hursky, V.S. & Price, K.E. BL-20803, a new, lowmolecular-weight interferon inducer. Antimicrob Agents Chemother 1973 Jun, 3(6), 742-743.
28. Glaz, E.T., Szolgay, E., Stoger, I. & Talas, M. Antiviral activity and induction of interferon-like substance by quinacrine and acranil. Antimicrob Agents Chemother 1973 May, 3(5), 537-541.
29. Hoffman, W.W., Korst, J.J., Niblack, J.F. & Cronin, T.H. N,N-Dioctadecyl-N',N'-bis(2-hydroxyethyl)propanediamine: antiviral activity and interferon stimulation in mice. Antimicrob Agents Chemother 1973 Apr, 3(4), 498-502.
30. Nichol, F.R., Weed, S.D. & Underwood, G.E. Stimulation of murine interferon by a substituted pyrimidine. Antimicrob Agents Chemother 1976 Mar, 9(3), 433-439.
31. Tamm, I. & Sehgal, P.B. A comparative study of the effects of certain halogenated benzimidazole ribosides on RNA synthesis, cell proliferation, and interferon production. J Exp Med 1977 Feb 1, 145(2), 344-356.
32. Taylor, J.L., Schoenherr, C.K. & Grossberg, S.E. High-yield interferon induction by 10-carboxymethyl-9-acridanone in mice and hamsters. Antimicrob Agents Chemother 1980 Jul, 18(1), 20-26.
33. Wierenga, W., Skulnick, H.I., Stringfellow, D.A., Weed, S.D., Renis, H.E. & Eidson, E.E. 5-Substituted 2-amino-6-phenyl-4(3H)-pyrimidinones. Antiviral-and interferon-inducing agents. J Med Chem 1980 Mar, 23(3), 237-239.
34. Wierenga, W. Antiviral and other bioactivities of pyrimidinones. Pharmacol Ther 1985, 30(1), 67-89.
35. Adam, A., Ed. Synthetic Adjuvants, 4th ed., Wiley, New York, 1985.
36. Smee, D.F., Alaghamandan, H.A., Cottam, H.B., Sharma, B.S., Jolley, W.B. & Robins, R.K. Broad-spectrum in vivo antiviral activity of 7-thia-8-oxoguanosine, a novel immunopotentiating agent. Antimicrob Agents Chemother 1989 Sep, 33(9), 1487-1492.
37. Parandoosh, Z., Ojo-Amaize, E., Robins, R.K., Jolley, W.B. & Rubalcava, B. Stimulation of phosphoinositide signaling pathway in murine B lymphocytes by a novel guanosine analog, 7-thia-8-oxoguanosine. Biochem Biophys Res Commun 1989 Sep 29, 163(3), 1306-1311.
38. Jin, A., Mhaskar, S., Jolley, W.B., Robins, R.K. & Ojo-Amaize, E.A. A novel guanosine analog, 7-thia-8-oxoguanosine, enhances macrophage and lymphocyte antibody-dependent cell-mediated cytotoxicity. Cell Immunol 1990 Apr 1, 126(2), 414-419.
39. Sharma, B.S., Mhaskar, S., Balazs, L. & Siaw, M. Immunomodulatory activity of a novel nucleoside, 7-thia-8-oxoguanosine: I. Activation of natural killer cells in mice. Immunopharmacol Immunotoxicol 1992, 14(1-2), 1-19.
40. Smee, D.F., Alaghamandan, H.A., Gilbert, J., Burger, R.A., Jin, A., Sharma, B.S. et al. Immunoenhancing properties and antiviral activity of 7-deazaguanosine in mice. Antimicrob Agents Chemother 1991 Jan, 35(1), 152-157.
41. Smee, D.F., Alaghamandan, H.A., Ramasamy, K. & Revankar, G.R. Broadspectrum activity of 8-chloro-7-deazaguanosine against RNA virus infections in mice and rats. Antiviral Res 1995 Mar, 26(2), 203-209.
42. Goodman, M.G., Gupta, S., Rosenthale, M.E., Capetola, R.J., Bell, S.C. & Weigle, W.O. Protein kinase C independent restoration of specific immune responsiveness in common variable immunodeficiency. Clin Immunol Immunopathol 1991 Apr, 59(1), 26-36.
43. Goodman, M.G., Reitz, A.B., Chen, R., Bobardt, M.D., Goodman, J.H. & Pope, B.L. Selective modulation of elements of the immune system by low molecular weight nucleosides. J Pharmacol Exp Ther 1995 Sep, 274(3), 1552-1557.
44. Gupta, S., Vayuvegula, B. & Gollapudi, S. Substituted guanine ribonucleosides as B cell activators. Clin Immunol Immunopathol 1991 Nov, 61(2 Pt 2), S21-S27.
45. Pope, B.L., Chourmouzis, E., Sigindere, J., Capetola, R.J. & Lau, C.Y. In vivo enhancement of murine natural killer cell activity by 7-allyl-8-oxoguanosine (loxoribine). Int J Immunopharmacol 1992 Nov, 14(8), 1375-1382.
46. Reitz, A.B., Goodman, M.G., Pope, B.L., Argentieri, D.C., Bell, S.C., Burr, L.E. et al. Small-molecule immunostimulants: synthesis and activity of 7,8-disubstituted guanosines and structurally related compounds. J Med Chem 1994 Oct 14, 37(21), 3561-3578.
47. Gerster, J.F., Lindstrom, K.J., Miller, R.L., Tomai, M.A., Birmachu, W., Bomersine, S.N. et al. Synthesis and structure-activity-relationships of 1H-imidazo[4,5-c]quinolines that induce interferon production. J Med Chem 2005 May 19, 48(10), 3481-3491.
48. Tomai, M.A., Gibson, S.J., Imbertson, L.M., Miller, R.L., Myhre, P.E., Reiter, M.J. et al. Immunomodulating and antiviral activities of the imidazoquinoline S-28463. Antiviral Res 1995 Nov, 28(3), 253-264.
49. Hirota, R., Tajima, S., Yoneda, Y., Tamayama, T., Watanabe, M., Ueda, K. et al. Alopecia of IFN-gamma knockout mouse as a model for disturbance of the hair cycle: a unique arrest of the hair cycle at the anagen phase accompanied by mitosis. J Interferon Cytokine Res 2002 Sep, 22(9), 935-945.
50. Kurimoto, A., Ogino, T., Ichii, S., Isobe, Y., Tobe, M., Ogita, H. et al. Synthesis and structure-activity relationships of 2-amino-8-hydroxyadenines as orally active interferon inducing agents. Bioorg Med Chem 2003 Dec 1, 11(24), 5501-5508.
51. Jin, G., Wu, C.C., Tawatao, R.I., Chan, M., Carson, D.A. & Cottam, H.B. Synthesis and immunostimulatory activity of 8-substituted amino 9-benzyladenines as potent Toll-like receptor 7 agonists. Bioorg Med Chem Lett 2006 Sep 1, 16(17), 4559-4563.
52. Isobe, Y., Kurimoto, A., Tobe, M., Hashimoto, K., Nakamura, T., Norimura, K. et al. Synthesis and biological evaluation of novel 9-substituted-8-hydroxyadenine derivatives as potent interferon inducers. J Med Chem 2006 Mar 23, 49(6), 2088-2095.
53. Colic, M., Vucevic, D., Vasilijic, S., Popovic, L., Pejanovic, V., Jandric, D. et al. Proliferation of spleen cells in culture stimulated by 7-thia-8-oxoguanosine: evidence that both B-and T-cells are the targets of its action. Methods Find Exp Clin Pharmacol 1999 Nov, 21(9), 583-590.
54. Pope, B.L., MacIntyre, J.P., Kimball, E., Lee, S., Zhou, L., Taylor, G.R. et al. The immunostimulatory compound 7-allyl-8-oxoguanosine (loxoribine) induces a distinct subset of murine cytokines. Cell Immunol 1995 May, 162(2), 333-339.
55. Ahonen, C.L., Gibson, S.J., Smith, R.M., Pederson, L.K., Lindh, J.M., Tomai, M.A. et al. Dendritic cell maturation and subsequent enhanced T-cell stimulation induced with the novel synthetic immune response modifier R-848. Cell Immunol 1999 Oct 10, 197(1), 62-72.
56. Wagner, T.L., Ahonen, C.L., Couture, A.M., Gibson, S.J., Miller, R.L., Smith, R.M. et al. Modulation of TH1 and TH2 cytokine production with the immune response modifiers, R-848 and imiquimod. Cell Immunol 1999 Jan 10, 191(1), 10-19.
57. Bishop, G.A., Hsing, Y., Hostager, B.S., Jalukar, S.V., Ramirez, L.M. & Tomai, M.A. Molecular mechanisms of B lymphocyte activation by the immune response modifier R-848. J Immunol 2000 Nov 15, 165(10), 5552-5557.
58. Bishop, G.A., Ramirez, L.M., Baccam, M., Busch, L.K., Pederson, L.K. & Tomai, M.A. The immune response modifier resiquimod mimics CD40-induced B cell activation. Cell Immunol 2001 Feb 25, 208(1), 9-17.
59. Lee, J., Wu, C.C., Lee, K.J., Chuang, T.H., Katakura, K., Liu, Y.T. et al. Activation of anti-hepatitis C virus responses via Toll-like receptor 7. Proc Natl Acad Sci USA 2006 Feb 7, 103(6), 1828-1833.
60. Akira, S. & Hemmi, H. Recognition of pathogen-associated molecular patterns by TLR family. Immunol Lett 2003 Jan 22, 85(2), 85-95.
61. Edwards, A.D., Diebold, S.S., Slack, E.M., Tomizawa, H., Hemmi, H., Kaisho, T. et al. Toll-like receptor expression in murine DC subsets: lack of TLR7 expression by CD8 alpha+ DC correlates with unresponsiveness to imidazoquinolines. Eur J Immunol 2003 Apr, 33(4), 827-833.
62. Hemmi, H., Kaisho, T., Takeuchi, O., Sato, S., Sanjo, H., Hoshino, K. et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol 2002 Feb, 3(2), 196-200.
63. Lee, J., Chuang, T.H., Redecke, V., She, L., Pitha, P.M., Carson, D.A. et al. Molecular basis for the immunostimulatory activity of guanine nucleoside analogs: activation of Toll-like receptor 7. Proc Natl Acad Sci USA 2003 May 27, 100(11), 6646-6651.
64. Gorden, K.B., Gorski, K.S., Gibson, S.J., Kedl, R.M., Kieper, W.C., Qiu, X. et al. Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8. J Immunol 2005 Feb 1, 174(3), 1259-1268.
65. Gorski, K.S., Waller, E.L., Bjornton-Severson, J., Hanten, J.A., Riter, C.L., Kieper, W.C. et al. Distinct indirect pathways govern human NK-cell activation by TLR-7 and TLR-8 agonists. Int Immunol 2006 Jul, 18(7), 1115-1126.
66. Bekeredjian-Ding, I.B., Wagner, M., Hornung, V., Giese, T., Schnurr, M., Endres, S. et al. Plasmacytoid dendritic cells control TLR7 sensitivity of naive B cells via type I IFN. J Immunol 2005 Apr 1, 174(7), 4043-4050.
67. Peng, G., Guo, Z., Kiniwa, Y., Voo, K.S., Peng, W., Fu, T. et al. Toll-like receptor 8-mediated reversal of CD4+ regulatory T cell function. Science 2005 Aug 26, 309(5739), 1380-1384.
68. Levy, O., Suter, E.E., Miller, R.L. & Wessels, M.R. Unique efficacy of Toll-like receptor 8 agonists in activating human neonatal antigen-presenting cells. Blood 2006 Aug 15, 108(4), 1284-1290.
69. Jurk, M., Kritzler, A., Schulte, B., Tluk, S., Schetter, C., Krieg, A.M. et al. Modulating responsiveness of human TLR7 and 8 to small molecule ligands with T-rich phosphorothiate oligodeoxynucleotides. Eur J Immunol 2006 Jul, 36(7), 1815-1826.
70. Schon, M.P., Schon, M. & Klotz, K.N. The small antitumoral immune response modifier imiquimod interacts with adenosine receptor signaling in a TLR7-and TLR8-independent fashion. J Invest Dermatol 2006 Jun, 126(6), 1338-1347.
71. Kono, T., Kondo, S., Pastore, S., Shivji, G.M., Tomai, M.A., McKenzie, R.C. et al. Effects of a novel topical immunomodulator, imiquimod, on keratinocyte cytokine gene expression. Lymphokine Cytokine Res 1994 Apr, 13(2), 71-76.
72. Schon, M.P. & Schon, M. Immune modulation and apoptosis induction: two sides of the antitumoral activity of imiquimod. Apoptosis 2004 May, 9(3), 291-298.
73. Schon, M.P., Wienrich, B.G., Drewniok, C., Bong, A.B., Eberle, J., Geilen, C.C. et al. Death receptor-independent apoptosis in malignant melanoma induced by the small-molecule immune response modifier imiquimod. J Invest Dermatol 2004 May, 122(5), 1266-1276.
74. Barnetson, R.S., Satchell, A., Zhuang, L., Slade, H.B. & Halliday, G.M. Imiquimod induced regression of clinically diagnosed superficial basal cell carcinoma is associated with early infiltration by CD4 T cells and dendritic cells. Clin Exp Dermatol 2004 Nov, 29(6), 639-643.
75. Kanneganti, T.D., Ozoren, N., Body-Malapel, M., Amer, A., Park, J.H., Franchi, L. et al. Bacterial RNA and small antiviral compounds activate caspase-1 through cryopyrin/Nalp3. Nature 2006 Mar 9, 440(7081), 233-236.
76. Hamilton-Miller, J.M. Immunopharmacology of antibiotics: direct and indirect immunomodulation of defence mechanisms. J Chemother 2001 Apr, 13(2), 107-111.
77. Dalhoff, A. & Shalit, I. Immunomodulatory effects of quinolones. Lancet Infect Dis 2003 Jun, 3(6), 359-371.
78. Razonable, R.R., Henault, M., Lee, L.N., Laethem, C., Johnston, P.A., Watson, H.L. et al. Secretion of proinflammatory cytokines and chemokines during amphotericin B exposure is mediated by coactivation of Toll-like receptors 1 and 2. Antimicrob Agents Chemother 2005 Apr, 49(4), 1617-1621.
79. Razonable, R.R., Henault, M., Watson, H.L. & Paya, C.V. Nystatin induces secretion of interleukin (IL)-1beta, IL-8, and tumor necrosis factor alpha by a Toll-like receptor-dependent mechanism. Antimicrob Agents Chemother 2005 Aug, 49(8), 3546-3549.
80. Horsmans, Y., Berg, T., Desager, J.P., Mueller, T., Schott, E., Fletcher, S.P. et al. Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection. Hepatology 2005 Sep, 42(3), 724-731.
81. Dockrell, D.H. & Kinghorn, G.R. Imiquimod and resiquimod as novel immunomodulators. J Antimicrob Chemother 2001 Dec, 48(6), 751-755.
82. Spruance, S.L., Tyring, S.K., Smith, M.H. & Meng, T.C. Application of a topical immune response modifier, resiquimod gel, to modify the recurrence rate of recurrent genital herpes: a pilot study. J Infect Dis 2001 Jul 15, 184(2), 196-200.
83. Harrison, C.J., Miller, R.L. & Bernstein, D.I. Reduction of recurrent HSV disease using imiquimod alone or combined with a glycoprotein vaccine. Vaccine 2001 Feb 8, 19(13-14), 1820-1826.
84. Vasilakos, J.P., Smith, R.M., Gibson, S.J., Lindh, J.M., Pederson, L.K., Reiter, M.J. et al. Adjuvant activities of immune response modifier R-848: comparison with CpG ODN. Cell Immunol 2000 Aug 25, 204(1), 64-74.
85. Tomai, M.A., Imbertson, L.M., Stanczak, T.L., Tygrett, L.T. & Waldschmidt, T.J. The immune response modifiers imiquimod and R-848 are potent activators of B lymphocytes. Cell Immunol 2000 Jul 10, 203(1), 55-65.
86. Burns, R.P., Jr., Ferbel, B., Tomai, M., Miller, R. & Gaspari, A.A. The imidazoquinolines, imiquimod and R-848, induce functional, but not phenotypic, maturation of human epidermal Langerhans' cells. Clin Immunol 2000 Jan, 94(1), 13-23.
87. Johnston, D. & Bystryn, J.C. Topical imiquimod is a potent adjuvant to a weaklyimmunogenic protein prototype vaccine. Vaccine 2006 Mar 10, 24(11), 1958-1965.
88. Rechtsteiner, G., Warger, T., Osterloh, P., Schild, H. & Radsak, M.P. Cutting edge: priming of CTL by transcutaneous peptide immunization with imiquimod. J Immunol 2005 Mar 1, 174(5), 2476-2480.
89. Craft, N., Bruhn, K.W., Nguyen, B.D., Prins, R., Lin, J.W., Liau, L.M. et al. The TLR7 agonist imiquimod enhances the anti-melanoma effects of a recombinant Listeria monocytogenes vaccine. J Immunol 2005 Aug 1, 175(3), 1983-1990.
90. Prins, R.M., Craft, N., Bruhn, K.W., Khan-Farooqi, H., Koya, R.C., Stripecke, R. et al. The TLR-7 agonist, imiquimod, enhances dendritic cell survival and promotes tumor antigen-specific T cell priming: relation to central nervous system antitumor immunity. J Immunol 2006 Jan 1, 176(1), 157-164.
91. Otero, M., Calarota, S.A., Felber, B., Laddy, D., Pavlakis, G., Boyer, J.D. et al. Resiquimod is a modest adjuvant for HIV-1 gag-based genetic immunization in a mouse model. Vaccine 2004 Apr 16, 22(13-14), 1782-1790.
92. Zuber, A.K., Brave, A., Engstrom, G., Zuber, B., Ljungberg, K., Fredriksson, M. et al. Topical delivery of imiquimod to a mouse model as a novel adjuvant for human immunodeficiency virus (HIV) DNA. Vaccine 2004 Apr 16, 22(13-14), 1791-1798.
93. Smorlesi, A., Papalini, F., Orlando, F., Donnini, A., Re, F. & Provinciali, M. Imiquimod and S-27609 as adjuvants of DNA vaccination in a transgenic murine model of HER2/neu-positive mammary carcinoma. Gene Ther 2005 Sep, 12(17), 1324-1332.
94. Thomsen, L.L., Topley, P., Daly, M.G., Brett, S.J. & Tite, J.P. Imiquimod and resiquimod in a mouse model: adjuvants for DNA vaccination by particle-mediated immunotherapeutic delivery. Vaccine 2004 Apr 16, 22(13-14), 1799-1809.
95. Weeratna, R.D., Makinen, S.R., McCluskie, M.J. & Davis, H.L. TLR agonists as vaccine adjuvants: comparison of CpG ODN and resiquimod (R-848). Vaccine 2005 Nov 1, 23(45), 5263-5270.
96. Wille-Reece, U., Flynn, B.J., Lore, K., Koup, R.A., Kedl, R.M., Mattapallil, J.J. et al. HIV Gag protein conjugated to a Toll-like receptor 7/8 agonist improves the magnitude and quality of Th1 and CD8+ T cell responses in nonhuman primates. Proc Natl Acad Sci USA 2005 Oct 18, 102(42), 15190-15194.
97. Wille-Reece, U., Wu, C.Y., Flynn, B.J., Kedl, R.M. & Seder, R.A. Immunization with HIV-1 gag protein conjugated to a TLR7/8 agonist results in the generation of HIV-1 gag-specific Th1 and CD8+ T cell responses. J Immunol 2005 Jun 15, 174(12), 7676-7683.
98. Wille-Reece, U., Flynn, B.J., Lore, K., Koup, R.A., Miles, A.P., Saul, A. et al. Tolllike receptor agonists influence the magnitude and quality of memory T cell responses after prime-boost immunization in nonhuman primates. J Exp Med 2006 May 15, 203(5), 1249-1258.
99. Ulevitch, R.J. Therapeutics targeting the innate immune system. Nat Rev Immunol 2004 Jul, 4(7), 512-520.
100. Pashine, A., Valiante, N.M. & Ulmer, J.B. Targeting the innate immune response with improved vaccine adjuvants. Nat Med 2005 Apr, 11(4 Suppl), S63-S68.